Oral delivery of the anti-tumor necrosis factor α domain antibody, V565, results in high intestinal and fecal concentrations with minimal systemic exposure in cynomolgus monkeys.

Autor: Crowe JS; a VHsquared Ltd. , Babraham , UK.; b VHsquared Ltd., Wellcome Sanger Institute , Hinxton , UK., Roberts KJ; b VHsquared Ltd., Wellcome Sanger Institute , Hinxton , UK., Carlton TM; b VHsquared Ltd., Wellcome Sanger Institute , Hinxton , UK., Maggiore L; b VHsquared Ltd., Wellcome Sanger Institute , Hinxton , UK., Cubitt MF; b VHsquared Ltd., Wellcome Sanger Institute , Hinxton , UK., Ray KP; a VHsquared Ltd. , Babraham , UK., Donnelly MC; a VHsquared Ltd. , Babraham , UK., Wahlich JC; a VHsquared Ltd. , Babraham , UK., Humphreys JI; a VHsquared Ltd. , Babraham , UK., Robinson JR; a VHsquared Ltd. , Babraham , UK., Whale GA; a VHsquared Ltd. , Babraham , UK., West MR; b VHsquared Ltd., Wellcome Sanger Institute , Hinxton , UK.

Publikováno v: Drug development and industrial pharmacy [Drug Dev Ind Pharm] 2019 Mar; Vol. 45 (3), pp. 387-394. Date of Electronic Publication: 2018 Nov 25.